PFEPfizer
$28.27+23% 1Y
$28.27
$22.4452 weeks$29.03
PFE in its own filings
Nothing in PFE's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
652
Events found in the filings · across 6,671 filings · the record starts in 1994
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 4, 2026
Most recent filing · Form 10-Q
- Record starts
- Mar 18, 1994
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Security removed from listing or deregistered4 occurrences · usually a matured note or preferred class, not the common shares
- 2022-03-07
- Material impairment4 occurrences
- 2011-02-01
- SEC comment-letter activity62 occurrences
- 2024-08-22
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 4, 2026Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance.Earnings release · press release
- Jun 18, 2026On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s …Director or officer change · Form 8-K
- May 5, 2026Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance.Earnings release · press release
- Feb 3, 2026Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance.Earnings release · press release
- Nov 21, 2025On November 21, 2025, Pfizer Inc. (the “Company”) completed a public offering of $500,000,000 aggregate principal amount of Floating Rate Notes due 2027 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of 3.875% Notes due 2027 (the “2027 Notes”), $1,000,000,000 aggregate principal amount of …Other event · Form 8-K
- Nov 13, 2025Results of Other Events On November 13, 2025, Pfizer Inc. (“Pfizer” or the “Company”) completed the previously announced acquisition of Metsera, Inc., a Delaware corporation (“Metsera”), pursuant to the Agreement and Plan of Merger, dated as of September 21, 2025, as amended by Amendment No. 1 to the Agreement and …Other event · Form 8-K
- Nov 4, 2025Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, General
The closest names by size in the same industry